Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-01-28 Regulatory Filings
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 18, 2019, which is a Current Report under the Securities Exchange Act of 1934. The content focuses on the change in the company's independent registered public accounting firm, detailing the selection process, prior accountants, and confirming letters. It includes no financial statements or detailed financial data but rather disclosures about auditor changes and related correspondence. This matches the description of a Regulatory Filing (RNS), as it is a general regulatory announcement and does not constitute a full audit report or annual report. The document length is 5730 characters, sufficient to contain substantive information but the content is clearly a regulatory announcement about auditor change, not the audit report itself.
2019-01-28 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text specifically mentions the completion of an acquisition-related transaction (return of partial ownership rights and payment of a debt related to a commercialization agreement). The document is short (3262 characters) and focuses on a specific event rather than comprehensive financial data or management discussion. It is not an Annual Report, Earnings Release, or Interim Report. The content fits the category of a Current Report announcing a material event, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other specific categories. Therefore, the best classification is Regulatory Filings (RNS).
2018-12-31 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 28, 2018. It announces that the FDA granted an Orphan Drug designation to BioVie for terlipressin. The document includes a press release as an exhibit. The content is an announcement of a specific event rather than a full financial report or detailed management discussion. The length is 3445 characters, which is relatively short and consistent with a current report announcing a material event. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. It is not an Annual Report, Earnings Release, or other detailed financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-11-29 English
FORM 10-Q FOR PERIOD ENDED SEPTEMBER 30, 2018
Interim / Quarterly Report Q1 2019
2018-11-14 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 1, 2018. The key content is under Item 5.02, which announces changes in the company's management team, including resignations and new appointments of officers. There is no financial data or detailed financial reporting, but rather an announcement of management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3578 characters, which is relatively short and consistent with a typical 8-K management change announcement. Therefore, the appropriate classification is MANG with high confidence.
2018-11-01 English
PRIMARY DOCUMENT
Director's Dealing
2018-11-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.